Ophthalmic Challenges in 2022
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
Mark Hillen
April 26, 2022
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
Dr. Sebastian Siebelman from the media outlet, “Digital Ophthalmology” interviews ELZA AG’s Chief Executive Officer, Nikki Hafezi, as part of their “Visionaries” series. Several topics
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Prof. Hafezi, Medical Director of the ELZA Institute in Dietikon, Zurich, Switzerland, co-authored a recently published paper that indicated that obese adults have a lower
TouchOphthalmology interviewed Prof. Farhad Hafezi on why it’s taken until now to have an effective epi-on CXL solution.
The Tear Film & Ocular Surface Society (TFOS) is a non-profit organization, created with the aim of advancing the field of tear film and ocular
“PACK-CXL is safe for use in bacterial keratitis cases. It also seems to add value in reducing healing time and improving final visual acuity while reducing the need for tectonic keratoplasty” noted the study authors.
Insieme21, an association for people with trisomy 21, their parents, carers, and relatives in German-speaking Switzerland, recently featured the ELZA Institute in the 2021 edition
It can be challenging to cross-link the eyes of wheelchair users – for the patient and clinic staff alike. One example of just how challenging
